News · 2026-08-03
Industry Warns 7-OH Ban May Sweep In Natural Kratom Leaf Through Pseudoindoxyl 'Zero Tolerance' Loophole
Source: Pain News Network
Why it matters
As the August 5 DEA deadline arrives, kratom advocates who originally supported the 7-OH ban are now alarmed that the DEA's proposed scheduling of mitragynine pseudoindoxyl could inadvertently criminalize natural leaf kratom — because no current test can distinguish naturally occurring pseudoindoxyl from manufactured levels.
The big picture
The American Kratom Association (AKA) led the push to ban synthetic 7-OH products, arguing they are dangerous opioid formulations distinct from traditional kratom leaf. But a separate DEA order targeting mitragynine pseudoindoxyl — a naturally occurring kratom alkaloid — has created what AKA lobbyist Mac Haddow calls 'enormous confusion' within Congress and DEA staff. Without a scientific carveout, any natural leaf kratom product that contains trace pseudoindoxyl could theoretically fall under the ban. Seven-OH manufacturers, for their part, argue that 7-OH produced by the body from natural leaf kratom is chemically indistinguishable from concentrated 7-OH products.
Key findings
- The AKA, which championed the ban on concentrated 7-OH, is now lobbying for a 'carveout' exempting natural pseudoindoxyl levels in botanical kratom from DEA scheduling.
- No validated test currently exists to measure mitragynine pseudoindoxyl levels in commercial products, making any threshold enforcement effectively impossible.
- 7-OH manufacturers counter that their products are metabolically equivalent to what the body produces from natural leaf kratom, challenging the scientific basis for distinguishing the two.
- North Dakota Gov. Armstrong declared a full kratom ban on August 3, making the state the latest to act ahead of the federal deadline.
- Vendors slashed 7-OH product prices in recent weeks as the August 5 deadline approached, with consumers rushing to purchase remaining inventory.
What they say
"That's part of the problem, the confusion," explained Mac Haddow, AKA lobbyist. "The same kind of carveout for pseudoindoxyl would be appropriate, even though it might not be quantifiable at normal testing levels."
Bottom line
The AKA's own anti-7-OH campaign may have created a legal trap for natural leaf kratom, with the pseudoindoxyl scheduling order potentially criminalizing botanical products that cannot even be reliably tested for compliance.